Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06455059 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia

Study acronym: CANOPY-HCH-3
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 20, 2026 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Start date: Jun 6, 2024 to Jun 17, 2024v4
  2. Trial status: Enrolling by Invitation to Active, Not Recruitingv3
  3. Study sites: 2 to 23
    • Start date changed from estimate of Jun 1, 2024 to Jun 6, 2024
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The intent and design of this Phase 3 study is to assess vosoritide as a therapeutic option for the treatment of children with hypochondroplasia (HCH).
Trial Details
NCT Number NCT06455059
Lead Sponsor BioMarin Pharmaceutical
Conditions
(from sponsor)		 Hypochondroplasia
Related terms Bone Diseases, Bone Diseases, Developmental, Dwarfism, Genetic Diseases, Inborn, Hypochondroplasia, Musculoskeletal Diseases, Osteochondrodysplasias
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov